The government shutdown has left the SEC quiet, but a Peninsula biotech managed to go public anyway, lighting a path to Wall ...

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

Will the return of biotech IPOs become the hottest fashion trend this fall? It’s still early in the season, but Evommune has become the latest indicator that drug developers are once again tempted by ...

Windlas Biotech Ltd (Windlas) has quietly positioned itself as one of the more interesting mid-cap plays on India’s pharmaceuticals outsourcing wave. The company, headquartered in Dehradun, is ...

MapLight Therapeutics is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The California-based ...

Trump's federal government shutdown could affect three Bay Area biotech IPOs. Here’s their plan to get through the process ...

Oct 6 (Reuters) - MapLight Therapeutics, a clinical-stage biotech backed by Novo Holdings, said on Monday it is targeting a valuation of up to $704.3 million in its U.S. initial public offering, amid ...

Evommune, which is developing drugs targeting the sources of chronic inflammatory diseases, filed for an initial public offering. The Palo Alto, Calif., company is seeking a New York Stock Exchange ...

Sheel Biotech, a diversified agri-biotech company specializing in tissue culture, organic farming, and greenhouse solutions, is set to make its debut on the NSE SME platform on October 8. The Rs 34 ...

MapLight Therapeutics Inc. will raise $258.9 million in an initial public offering and private placement, becoming the first ...

The death of William (Bill) Rutter at the grand old age of 97 in July reminded me to remember not only him, but several of the other pioneers of our industry—lest we should forget them. In the late ...